NetworkNewsBreaks – Lexaria Bioscience Corp. (CS
Post# of 721
(Total Views: 324)
Posted On: 01/22/2020 3:09:22 PM
NetworkNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Provide Patented DehydraTECH(TM) to Cannadips’ Cannabis Products in California and Across the US
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products, both in its current California market and across the United States. According to the update, Lexaria’s DehydraTECH fast-acting, high-absorption technology is perfectly suited to improve consumer satisfaction and the dipping experience. Terpene-rich multi spectrum oils are base ingredients of Cannadips THC, and DehydraTECH is able to reduce throat irritation normally associated with some terpenes. Inferior products utilize less efficacious cannabis isolate without terpenes that lack the entourage effect derived from multi-spectrum oils in an attempt to get around this problem. “Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,” Lexaria Bioscience CEO Chris Bunka stated in the news release. “Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets that are either recreational or medical cannabis states, while preserving the brand rights as states come online through regulation.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced that it has reached a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products, both in its current California market and across the United States. According to the update, Lexaria’s DehydraTECH fast-acting, high-absorption technology is perfectly suited to improve consumer satisfaction and the dipping experience. Terpene-rich multi spectrum oils are base ingredients of Cannadips THC, and DehydraTECH is able to reduce throat irritation normally associated with some terpenes. Inferior products utilize less efficacious cannabis isolate without terpenes that lack the entourage effect derived from multi-spectrum oils in an attempt to get around this problem. “Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,” Lexaria Bioscience CEO Chris Bunka stated in the news release. “Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets that are either recreational or medical cannabis states, while preserving the brand rights as states come online through regulation.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼